Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: Results of the target dose study

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1821-1827

  Ducobu, Jean ^a   Claeys, Marc ^b   Commers, Kathleen ^c   Van Mieghem, W ^d   Nachtergaele, H ^e   Vandenbroucke, M ^f   Deforce, J ^g  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c PFIZER INC   (United States)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e Heilig Hart Ziekenhuis   (Belgium)

^f Algemeen Ziekenhuis Sint Maarten   (Belgium)

^g Centre Hospitalier de Tivoli ^*

Author keywords

Atorvastatin; Coronary heart disease; Dose selection; High risk; Low density lipoprotein cholesterol

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BRONCHITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEMENTIA; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTOXICATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FALLING; FEMALE; GASTRITIS; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMEROSCAPULAR PERIARTHRITIS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE ADENOCARCINOMA; SEPSIS; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TREATMENT OUTCOME;

EID: 34548118276     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210651     Document Type: Article

References (26)

1. World Health Organization. The world health report 2002: risks to health 2002. Geneva: World Health Organization; 2002
2. Haskell WL. Cardiovascular disease prevention and lifestyle interventions: effectiveness and efficacy. J Cardiovasc Nurs 2003;18:245-55
3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998;279:1615-22
4. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-57
5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996;335:1001-9
6. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
7. National Cholesterol Education Program Expert Panel. Executive summary of the third report on detection, evaluation, and treatment of high blood cholesterol in adults [Adult Treatment Panel III]. J Am Med Assoc 2001;285:2486-97
8. Wood DA, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice [Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention]. Eur Heart J 1998;19:1434-503
9. Bakker-Arkema RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 2000;149:123-9
10. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Arteriosclerosis 1997;130:191-7
11. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998;47:349-56
12. Anon. Physicians' desk reference. Lipitor (atorvastatin), 54th ed. Medical Economics Company Inc.: 2000. p. 2254-7
13. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82
14. Conroy RM, Pyorala K, Fitzgerald S, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
15. Claeys MJ, Cosyns B, Hoffer E, et al.; Belgian Young Cardiologists' Club. Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease. Acta Cardiol 2004;59:269-74
16. Kakafika A, Tsimihodimos V, Elisaf M. Effect of atorvastatin on serum uric acid levels. Atherosclerosis 2001;158:255
17. Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004;148:635-40
18. Athyros VG, Elisaf M, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
19. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285:2486-97
20. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice [Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. Eur Heart J 2003;24:1601-10
21. McKenney JM, Davidson MH, Saponaro J, et al. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol 2005;46:594-9
22. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2007;191:135-46
23. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New Engl J Med 2001;344:1959-65
24. Afonso NM, Nassif G, Aranha AN, et al. Low-density lipoprotein cholesterol goal attainment among high-risk patients: does a combined intervention targeting patients and providers work? Am J Manag Care 2006;12:589-94
25. Garcia Ruiz FJ, Marin IA, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY study. Pharmacoeconomics 2004;22(Suppl 3):1-12
26. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83